Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compound preparation for treating different types of ametropia

A refractive error and compound preparation technology, applied in the field of medicine, can solve problems such as side effects, poor effect, lack of effective drugs for treating refractive errors, etc., and achieve the effects of obvious differences, reduced surgical pain, and reduced economic burden.

Active Publication Date: 2014-08-06
王巨龙
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

How to improve the cure rate of refractive error and reduce its disability rate, and maintain the healthy growth of children is the responsibility of modern ophthalmology medical care, but there is a lack of effective drugs for treating refractive error in the prior art. In the prior art, physical therapy is mostly used Correction of refractive error, but there are more or less problems such as poor effect or side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound preparation for treating different types of ametropia
  • Compound preparation for treating different types of ametropia
  • Compound preparation for treating different types of ametropia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1~10

[0036] 1. Preparation of each component: The following components by weight are used to prepare the compound preparations of Examples 1-10, see Table 2 for details:

[0037] The composition ratio of table 2 embodiment 1~10

[0038]

[0039] Wherein, used component adds with following form:

[0040] Inosine Injection (manufactured by Linzhou Yashen Pharmaceutical Co., Ltd., specification 2ml: 0.1g, approved by the State Drug Administration H41022233);

[0041] Eye aminopeptide injection (Tianjin Biochemical Pharmaceutical Co., Ltd., specification 2ml: equivalent to 2g of fresh bull's eyeball, approved by the Chinese Medicine H12021052);

[0042] Citicoline Sodium Injection (Jinan Limin Pharmaceutical Co., Ltd., specification 2ml: 0.25g, National Drug Approval H37021222);

[0043] Adenosine triphosphate disodium injection (Bikang Pharmaceutical Jiangsu Co., Ltd., specification 2ml: 20mg, national drug approval H32023506);

[0044] Cerebroprotein hydrolyzate injection (Shaa...

Embodiment 11

[0046] Embodiment 11 Adopt the compound preparation that embodiment 1 makes to the treatment result of hyperopic amblyopia

[0047] 1. Treatment object: A total of 710 cases of children and adolescents aged 3-19 were admitted to Shijiazhuang Union Medical College Myopia, Hyperopia, Strabismus and Amblyopia Eye Disease Research Institute from 2005 to 2014.

[0048] 2. Case inclusion criteria: According to the standards in Table 1, if the eye axis is lower than the normal value, it belongs to hyperopic amblyopia. According to the international eye chart, the visual acuity is 0.01 or below.

[0049] 3. Evaluation criteria: according to the international eye chart, the visual acuity exceeding 0.1 is markedly effective; the visual acuity recovering from 0.01 to 1.2~1.5 and the eye axis returning to the normal range are cured.

[0050] 4. Administration method: use the eye cup method to administer the medicine locally, once a day, 30 minutes each time, 10 days as a course of treat...

Embodiment 12

[0056] Embodiment 12 to the treatment result of myopia

[0057] 1. Treatment object: A total of 1,329 cases of children and adolescents aged 3-19 were admitted to Shijiazhuang Union Medical College Myopia, Hyperopia, Strabismus and Amblyopia Eye Disease Research Institute from 2005 to 2014.

[0058] 2. Case inclusion criteria: Moderate and mild myopia: according to the international eye chart, visual acuity 0.1~0.5, eye axis longer than normal, diopter within 300°; high myopia: visual acuity 0.01 and below, diopter 2000~1800°, according to Table 1 Standard, the eye axis is 9mm-3mm longer than the normal value 。

[0059] 3. Cure standard: moderate and mild myopia: visual acuity returns to 1.2~1.5, eye axis returns to normal value; severe myopia: visual acuity returns to 0.6, diopter returns to 1000°~800°, diopter stops deepening 。

[0060] 4. Administration method: use the eye cup method to administer the medicine locally, once a day, 30 minutes each time, 10 days as a cou...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a compound preparation for treating different types of ametropia, which can effectively treat shortsightedness, hyperopia, amblyopia, strabismus and the like, is free of toxic and side effects, and can avoid reappear basically after ametropia is cured. The compound preparation comprises the following components in parts by weight: 1-3 parts of inosine, 35-45 parts of ocular extractives, 3-12 parts of citicoline sodium, 0.3-1 part of trinosin and 0-0.3 part of cerebroprotein hydrolysate, wherein the weight of the ocular extractives is based on the weight of the ocular extractives relative to a fresh bovine eye; the weight of the cerebrolysin vial is based on total nitrogen weight. A lot of clinical tests prove that the significant efficiency of the preparation disclosed by the invention is 100%, the recovery rate is over 90%; compacted with each single component, the compound preparation is quite different in effect, and the medical treatment blank of various types of ametropia is successfully filled.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a compound preparation for treating different types of ametropia. Background technique [0002] Refractive error is an important problem affecting eye health. Refractive error includes myopia and amblyopia, and amblyopia includes myopic amblyopia, hyperopic amblyopia, strabismic amblyopia and mixed astigmatism. Refractive errors caused by different reasons have a great impact on the healthy growth of young people, and also pose great challenges to our country's medical care and education. [0003] In 2008, the Chinese Academy of Ophthalmology Children's Amblyopia and Strabismus Prevention Group conducted a nationwide survey of refractive errors, showing that 1,080 of the 37,745 subjects suffered from amblyopia, accounting for 2.86% of the subjects. At present, there are 40 million amblyopia patients in my country. In recent years, the prevalence of amblyopia has be...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/01A61P27/10A61K31/7076A61K31/708A61K31/7068
Inventor 张淑清王铭维
Owner 王巨龙
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com